Literature DB >> 11756653

Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.

M D Kaeser1, R D Iggo.   

Abstract

p53 can adopt two forms in vitro, a latent form that binds naked DNA poorly and an active form that binds DNA well. Conversion of the latent form to the active form is thought to occur by an allosteric mechanism induced by phosphorylation and acetylation. Despite the large differences in affinity produced by regulatory modifications in vitro, mutation of putative regulatory sites has not produced correspondingly large effects on transcription of p53 target genes in vivo. To determine whether genotoxic stress regulates DNA binding by p53 in vivo, we have performed quantitative chromatin immunoprecipitation (ChIP) assays on tumor and normal cell lines containing wild-type p53. ChIP recovers several hundredfold more p21 and MDM2 promoter DNA from p53 wild-type than p53-null cells, indicating that the assay is specific for p53. Genotoxic stress induces much smaller increases in chromatin precipitation, which are matched by changes in the p53 protein level. Thus, in the experimental systems tested, allosteric regulation of DNA binding is not a major level of regulation of p53 activity. The p53 target genes tested can be divided into a group showing high promoter occupancy in vivo (p21, MDM2, and PUMA) and a group giving substantially weaker or background p53 binding (bax, AIP1, and PIG3). Neither group shows selective recruitment of p53 to the promoter in cells undergoing apoptosis, indicating that the decision to undergo apoptosis or cell cycle arrest depends on other changes in the cell.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756653      PMCID: PMC117520          DOI: 10.1073/pnas.012283399

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

Review 1.  Mechanisms of switching on p53: a role for covalent modification?

Authors:  D W Meek
Journal:  Oncogene       Date:  1999-12-13       Impact factor: 9.867

2.  DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation.

Authors:  C Blattner; E Tobiasch; M Litfen; H J Rahmsdorf; P Herrlich
Journal:  Oncogene       Date:  1999-03-04       Impact factor: 9.867

3.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

4.  Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding.

Authors:  Q Zhan; I T Chen; M J Antinore; A J Fornace
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

5.  Increased apoptosis induction by 121F mutant p53.

Authors:  E Saller; E Tom; M Brunori; M Otter; A Estreicher; D H Mack; R Iggo
Journal:  EMBO J       Date:  1999-08-16       Impact factor: 11.598

6.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Authors:  F Bunz; P M Hwang; C Torrance; T Waldman; Y Zhang; L Dillehay; J Williams; C Lengauer; K W Kinzler; B Vogelstein
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

7.  DNA damage induces phosphorylation of the amino terminus of p53.

Authors:  J D Siliciano; C E Canman; Y Taya; K Sakaguchi; E Appella; M B Kastan
Journal:  Genes Dev       Date:  1997-12-15       Impact factor: 11.361

8.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.

Authors:  R L Ludwig; S Bates; K H Vousden
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

9.  Regulation of p53 function and stability by phosphorylation.

Authors:  M Ashcroft; M H Kubbutat; K H Vousden
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

10.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.

Authors:  X Chen; L J Ko; L Jayaraman; C Prives
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

View more
  109 in total

1.  Interactions between p53, hMSH2-hMSH6 and HMG I(Y) on Holliday junctions and bulged bases.

Authors:  Deepa Subramanian; Jack D Griffith
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

2.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells.

Authors:  Jian Yu; Zhenghe Wang; Kenneth W Kinzler; Bert Vogelstein; Lin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

3.  Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein.

Authors:  Kristine McKinney; Carol Prives
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

4.  Regulation of ultraviolet light-induced gene expression by gene size.

Authors:  Bruce C McKay; Lawton J Stubbert; Casey C Fowler; Jennifer M Smith; Robin A Cardamore; Jennifer C Spronck
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-15       Impact factor: 11.205

5.  Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes.

Authors:  Nathan P Gomes; Joaquín M Espinosa
Journal:  Cell Cycle       Date:  2010-09-13       Impact factor: 4.534

6.  Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.

Authors:  Carol Imbriano; Aymone Gurtner; Fabienne Cocchiarella; Silvia Di Agostino; Valentina Basile; Monica Gostissa; Matthias Dobbelstein; Giannino Del Sal; Giulia Piaggio; Roberto Mantovani
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

7.  Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.

Authors:  Kasandra J-L Riley; Laura A Cassiday; Akash Kumar; L James Maher
Journal:  RNA       Date:  2006-04       Impact factor: 4.942

8.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

9.  The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Authors:  Lu-Zhe Pan; Dae-Gyun Ahn; Tanveer Sharif; Derek Clements; Shashi A Gujar; Patrick W K Lee
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

10.  Transcription of mammalian messenger RNAs by a nuclear RNA polymerase of mitochondrial origin.

Authors:  Julia E Kravchenko; Igor B Rogozin; Eugene V Koonin; Peter M Chumakov
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.